Previous 10 | Next 10 |
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2024 financial resu...
The first fully implantable continuous glucose monitors can now be integrated with insulin pumps as part of an automated insulin delivery system Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, impla...
SAVINGS OFFER FOR THE EVERSENSE E3 CGM EXTENDED TO COVER UNLIMITED NUMBER OF SYSTEMS PR Newswire Eligible individuals in the U.S. will pay $99 out of pocket for each 6-month CGM system, offering each year of continuous glucose monitoring for just $200* PA...
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced data from the Eversense ® Post Approval Study is to b...
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Oppenheimer Healthcare Me...
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter and full year ended December ...
Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Blue Horizon Global Capital Corp. (CSE: BHCC) (" BHCC "), an investment company whose primary objective is to identify promising companies with excellent projects, innovative technologies, or both, is pleased to announce that 14125339 Canad...
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2023...
MEDICARE COVERAGE SIGNIFICANTLY EXPANDED FOR THE EVERSENSE E3 CGM SYSTEM PR Newswire The decision is further recognition of Eversense as an important option for people with diabetes PARSIPPANY, N.J. , Feb. 12, 2024 /PRNewswire/ -- Ascensia Diabe...
The decision is further recognition of Eversense as an important option for people with diabetes Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long...
News, Short Squeeze, Breakout and More Instantly...
Senseonics Holdings Inc. Company Name:
SENS Stock Symbol:
NYSE Market:
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Sidoti Small Cap Conferen...
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended March 31, 2024. R...
Enhancing patient care and advancing innovation with the only long-term implantable continuous glucose monitor Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitor ...